EICHOR
● Active Not Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Condition: Locally Advanced Solid Tumors · Recurrent Solid Tumors · Metastatic Solid Tumors · Sponsor: Genentech, Inc.
About this study
This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (18)
| University of Alabama at Birmingham (UAB) | Birmingham, Alabama, United States | — |
| Yale Cancer Center | New Haven, Connecticut, United States | — |
| Icahn School of Medicine at Mount Sinai (ISMMS) | New York, New York, United States | — |
| The Ohio State University | Columbus, Ohio, United States | — |
| Magee-Woman's Hospital | Harrisburg, Pennsylvania, United States | — |
| SCRI Oncology Partners | Nashville, Tennessee, United States | — |
| St Vincent's Hospital Sydney | Darlinghurst, New South Wales, Australia | — |
| Peter Maccallum Cancer Centre | Melbourne, Victoria, Australia | — |
| British Columbia Cancer Agency - 600 10th Ave W | Vancouver, British Columbia, Canada | — |
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | — |
| National University Hospital | Singapore, Singapore | — |
| National Cancer Centre | Singapore, Singapore | — |
+ 6 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06031441